NCT05377827

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

SUSPENDEDPHASE1INTERVENTIONAL

Trial Details

Start: 2023-10-10Est. Completion: 2027-06-30

Enrollment target: 6 participants

Locations

B-cell Acute Lymphoblastic LeukemiaDiffuse Large B-cell LymphomaBurkitt LymphomaNeuroblastomaEwing Sarcoma

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab…

Los Angeles, United StatesEst. completion Mar 31, 2029

Recurrent Burkitt LymphomaRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 RearrangementsRefractory Burkitt Lymphoma

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.